Mohammed A. Aljama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammed A. Aljama has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- M. Hasib Sidiqi
Division of Hematology Mayo Clinic Rochester Minnesota
1 shared publication - Omar Alkharabsheh
Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH 45267, USA
1 shared publication - Sunil Badami
Division of Hematology-Oncology in the Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA
1 shared publication - Zachary Trisel
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA
1 shared publication
Latest Publications
- Open Access
Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises
Immune dysregulation and alteration of the bone marrow microenvironment allowing plasma cells to escape immune surveillance are well-known factors associated with the proliferation of clonal plasma cells and development of multiple myeloma (MM). Whilst immunotherapeutic approaches are now commonplace in a wide spectrum of malignancies, this aberration of myeloma development gives rise to the biological rationale for the use of immune checkpoint inhibitors (ICIs) in MM. However, the initial experience with these agents has been challenging with limited single agent efficacy, significant toxicity, and side effects. Herein, we review the biological and immunological aspects of MM and ICIs. We discuss the basic biology of immune checkpoint inhibitors, mechanisms of resistance, and drug failure patterns, review the published clinical trial data for ICIs in MM, and look towards the future of ICIs for MM treatment.
Open AccessCheckpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises
Immune dysregulation and alteration of the bone marrow microenvironment allowing plasma cells to escape immune surveillance are well-known factors associated with the proliferation of clonal plasma cells and development of multiple myeloma (MM). Whilst immunotherapeutic approaches are now commonplace in a wide spectrum of malignancies, this aberration of myeloma development gives rise to the biological rationale for the use of immune checkpoint inhibitors (ICIs) in MM. However, the initial experience with these agents has been challenging with limited single agent efficacy, significant toxicity, and side effects. Herein, we review the biological and immunological aspects of MM and ICIs. We discuss the basic biology of immune checkpoint inhibitors, mechanisms of resistance, and drug failure patterns, review the published clinical trial data for ICIs in MM, and look towards the future of ICIs for MM treatment.